GRAIL, Inc. (GRAL)
Sector: Services-Medical Laboratories
Industry: Medical - Diagnostics & Research
GRAIL Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 122.00 | 129.70 | 117.00 | 121.44 | 756,383 |
| Nov 5, 2026 | 119.50 | 130.00 | 117.21 | 119.13 | 2,096,581 |
| Nov 4, 2026 | 140.30 | 143.82 | 132.02 | 143.66 | 764,527 |
| Nov 3, 2026 | 136.97 | 144.23 | 136.66 | 139.44 | 1,272,940 |
| Nov 2, 2026 | 148.53 | 149.00 | 132.13 | 133.76 | 983,305 |
| Oct 30, 2026 | 152.08 | 155.18 | 141.00 | 143.43 | 1,073,440 |
| Oct 29, 2026 | 156.27 | 161.90 | 155.69 | 158.92 | 761,501 |
| Oct 28, 2026 | 150.61 | 160.25 | 149.37 | 157.88 | 1,151,787 |
| Oct 27, 2026 | 139.07 | 153.26 | 139.01 | 150.61 | 1,934,550 |
| Oct 26, 2026 | 134.83 | 141.68 | 132.75 | 139.91 | 891,370 |
| Oct 23, 2026 | 128.12 | 135.94 | 125.00 | 132.55 | 575,098 |
| Oct 22, 2026 | 133.13 | 133.90 | 123.26 | 127.06 | 653,259 |
| Oct 21, 2026 | 123.88 | 134.91 | 123.20 | 132.60 | 599,659 |
| Oct 20, 2026 | 120.07 | 128.52 | 118.66 | 124.67 | 738,858 |
| Oct 19, 2026 | 117.68 | 124.50 | 117.58 | 122.42 | 578,716 |
| Oct 16, 2026 | 134.02 | 136.50 | 117.06 | 117.81 | 1,305,943 |
| Oct 15, 2026 | 136.00 | 139.50 | 132.09 | 135.46 | 701,512 |
| Oct 14, 2026 | 139.79 | 144.18 | 138.00 | 139.70 | 826,630 |
| Oct 13, 2026 | 138.09 | 142.17 | 135.24 | 140.35 | 703,107 |
| Oct 12, 2026 | 137.41 | 140.49 | 133.86 | 137.37 | 651,106 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Ofman Joshua J. | Chief Executive Officer | Sale | 2.1K | $293.4K | Oct 15, 2026 |
| Ofman Joshua J. | Chief Executive Officer | Sale | 7.1K | $964.9K | Oct 15, 2026 |
| Ofman Joshua J. | Chief Executive Officer | Sale | 6.0K | $830.5K | Oct 15, 2026 |
 CHASE WILLIAM J | Director | Grant/Award | 153 | $20.7K | Oct 15, 2026 |
 MIZELL STEVEN | Director | Grant/Award | 148 | $20.0K | Oct 15, 2026 |
 SUMME GREGORY L | Director | Grant/Award | 237 | $32.1K | Oct 15, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Farallon Capital Management, L.L.C. · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 4.2M | 9.3% | 13G |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 4.2M | 9.3% | 13F |
Baker Bros. Advisors LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 4.0M | 9.0% | 13G |
BAKER BROS. ADVISORS LP | 4.0M | 9.0% | 13F |
BlackRock, Inc. | 3.6M | 8.0% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2026 | 3.4M | 7.5% | 13G |
STATE STREET CORP | 2.4M | 5.3% | 13F |
PRIMECAP MANAGEMENT CO/CA/ · also on 13F· may incl. warrants· filed Nov 2026 | 2.2M | 4.9% | 13G |
PRIMECAP MANAGEMENT CO/CA/ | 2.2M | 4.8% | 13F |
Sessa Capital IM, L.P. | 2.0M | 4.5% | 13F |
Insiders
- Ofman Joshua J.Chief Executive Officer
- CHASE WILLIAM JDirector
- MIZELL STEVENDirector
- SUMME GREGORY LDirector
- Partridge Andrew JohnChief Growth Officer
- Freidin AaronChief Financial Officer
- Krevans SarahDirector
- RAGUSA ROBERT PChief Executive Officer
- ILLUMINA, INC.10% Owner
- DING CHUN R10% Owner
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring.
The company was incorporated in 2015 and is headquartered in Menlo Park, California.
based on 44.96M shares outstanding
US30d Avg
951.01K
60d Avg
1.31M
90d Avg
1.07M